Roivant Sciences Ltd

NASDAQ:ROIV   3:59:53 PM EDT
3.84
-0.20 (-4.95%)
Earnings Announcements

Roivant Sciences Reports Financial Results For The Fourth Quarter And Fiscal Year Ended March 31, 2022 And Provides Business Update

Published: 06/28/2022 11:32 GMT
Roivant Sciences Ltd (ROIV) - Roivant Sciences Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022 and Provides Business Update.
Implemented a Company-wide Cost Optimization and Pipeline Reprioritization Initiative.
Discontinued Development of Several Programs, Including Aru-1801, Lsvt-1701, Dmvt-502, Dmvt-503, Dmvt-504 and Cvt-tcr-01.
Elected to Wind Down Development of Aru-1801.
As of March 31, 2022, We Had Cash and Cash Equivalents of Approximately $2.1 Billion.
Qtrly Net Loss per Common Share-basic and Diluted$0.39.
Q4 Earnings per Share View $-0.32 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $7.08 Million
Adjusted EPS is expected to be -$0.39

Next Quarter Revenue Guidance is expected to be $8.62 Million
Next Quarter EPS Guidance is expected to be -$0.38

More details on our Analysts Page.